Table 2.
The estimated treatment effects for dementia over balanced drug classes.
| Drug class | ATC codes | # BT | # Users | # Non-users | *UR (%) | mean ATE (95% CI) | Significance (p-value) |
|---|---|---|---|---|---|---|---|
| After reweighting | |||||||
| Diuretics | C03 | 83 | 1366 | 1729 | 1.79 | 0.0328 (0.0255, 0.0401) | < 0.001 |
| Low-ceiling diuretics, thiazides | C03A | 100 | 1327 | 474 | 1.78 | 0.0268 (0.0198, 0.0339) | < 0.001 |
| Beta blockers | C07 | 100 | 2661 | 2631 | 1.73 | 0.0221 (0.0141, 0.0300) | < 0.001 |
| BBAs | C07A | 100 | 1404 | 494 | 1.10 | − 0.0266 (− 0.0341, − 0.019) | < 0.001 |
| BBAs and thiazides | C07B | 100 | 1532 | 1012 | 1.55 | 0.0221 (0.0150, 0.0291) | < 0.001 |
| BBAs and other diuretics | C07C | 100 | 1583 | 1081 | 1.73 | 0.0341 (0.0288, 0.0395) | < 0.001 |
| BBAs, other combinations | C07F | 100 | 1946 | 697 | 1.11 | 0.0147 (0.0075, 0.022) | < 0.001 |
| CCBs | C08 | 100 | 719 | 1083 | 1.75 | 0.0211 (0.0138, 0.0284) | < 0.001 |
| Selective CCBs with mainly vascular effects | C08C | 100 | 743 | 246 | 1.06 | − 0.0458 (− 0.0593, − 0.0324) | < 0.001 |
| Dihydropyridine derivatives | C08CA | 100 | 745 | 248 | 1.05 | − 0.0571 (− 0.0692, − 0.0451) | < 0.001 |
| Agents acting on the renin-angiotensin system | C09 | 93 | 856 | 1140 | 1.68 | 0.0270 (0.0201, 0.0338) | < 0.001 |
| ACE-inhibitors | C09A | 100 | 1145 | 1544 | 1.72 | 0.0341 (0.0283, 0.0399) | < 0.001 |
| ACE inhibitors, combine | C09B | 100 | 1279 | 1589 | 1.25 | 0.1205 (0.1131, 0.1279) | < 0.001 |
| ARBs | C09C | 100 | 1267 | 1435 | 1.24 | 0.0020 (− 0.0037, − 0.0077) | ns |
| ARBs, combinations | C09D | 100 | 1326 | 1538 | 1.19 | 0.0974 (0.0899, 0.1049) | < 0.001 |
| Statin | C10AA | 100 | 2948 | 1001 | 0.98 | 0.0592 (0.0543, 0.0641) | < 0.001 |
| SSRIs | N06AB | 100 | 1897 | 2658 | 1.63 | − 0.0210 (− 0.0259, − 0.0162) | < 0.001 |
| PPIs | A02BC | 100 | 2139 | 758 | 1.71 | 0.0274 (0.0224, 0.0324) | < 0.001 |
*BT:balanced trials; *UR:unbalanced ratio, ns=non-significant.